AbbVie submits regulatory application to EMA for Skyrizi
AbbVie has submitted a regulatory application to the EMA for Skyrizi.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
AbbVie submits EMA regulatory application for SKYRIZI Crohn’s induction
AbbVie submitted a regulatory application to the EMA for SKYRIZI subcutaneous induction in adults with moderately to severely active Crohn’s disease.